VENTOLIN NEBULES P.F. - 5MG/2.5ML SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

SALBUTAMOL (SALBUTAMOL SULFATE)

Διαθέσιμο από:

GLAXOSMITHKLINE INC

Φαρμακολογική κατηγορία (ATC):

R03AC02

INN (Διεθνής Όνομα):

SALBUTAMOL

Δοσολογία:

5MG

Φαρμακοτεχνική μορφή:

SOLUTION

Σύνθεση:

SALBUTAMOL (SALBUTAMOL SULFATE) 5MG

Οδός χορήγησης:

INHALATION

Μονάδες σε πακέτο:

2.5ML DOSE X 20

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0108887001; AHFS:

Καθεστώς αδειοδότησης:

CANCELLED POST MARKET

Ημερομηνία της άδειας:

2022-07-05

Αρχείο Π.Χ.Π.

_ _
_ _
_Page 1 of 33_
_ _
PRODUCT MONOGRAPH
PR
VENTOLIN
RESPIRATOR SOLUTION
salbutamol sulfate solution
5 mg/mL
PR
VENTOLIN NEBULES P.F.
salbutamol sulfate solution
2.5 mg/2.5 mL, 5 mg/2.5 mL ampoules
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 17, 2017
Submission Control No: 207158
© 2017 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK
group of companies.
_ _
_ _
_Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
.........................................................